Immune to Cancer: The CRI Blog
-
Cindy Stowell Continues to Inspire
Jeopardy! host Alex Trebek will make a special announcement on Tuesday, November 7th.
-
CRI Researcher Highlights New Technique to Aid Immunotherapy
Dr. Mohammad Rashidian’s nanobodies could help improve doctors’ decisions regarding immunotherapy.
-
Corporate Social Responsibility Gives Cancer Immunotherapy Research a “Wonderful Edge”
Cupid Intimates spearheaded a corporate social responsibility initiative that generated a $10,000 donation to CRI’s immunotherapy research…
-
CAR T Cell Immunotherapy Approved for Adult Non-Hodgkin Lymphoma Patients
FDA approves new immunotherapy–Yescarta (axicabtagene ciloleucel)–for adult patients with relapsed or refractory non-Hodgkin large B cell lymphoma.
-
CRI featured in USA Today’s End-of-Year Charity Giving Advice
CRI among 12 top-rated cancer charities within a subset of organizations doing good work in breast cancer…
-
Checkpoint Immunotherapy Approved for Patients with Stomach, Gastroesophageal, and Liver Cancer
Previously treated patients with these cancer types can now receive anti-PD-1 immunotherapy; nivolumab for HCC and pembrolizumab…
-
CICON17 Day 4 Recap: The Tumor Microenvironment and Oncolytic Viruses
The final day of CICON17 explored two newer immunotherapy approaches that reflect broader understanding of tumor-immune interactions…
-
CICON17 Day 3 Recap: Combinations, Checkpoint Immunotherapy Resistance, Immunomodulators, and Microbiota
Day 3 of the CICON17 focused on combination therapies, immunomodulators, overcoming immune suppression, and the role bacteria in…
-
CICON17 Day 2 Recap: Biomarkers, Novel Agents, and Adoptive Cell Therapies
Day 2 of CICON17 offered a focused exploration of the latest discoveries and data from scientific studies…
Join CRI in Shaping the Future of Immunotherapy
Support the pioneering work of CRI in advancing immunotherapy.